Abstract
BACKGROUND: Histopathological interpretation of Barrett's oesophagus-associated dysplasia remains variable, and although guidelines recommend expert pathology review, specialist capacity is increasingly constrained. We assessed the real-world diagnostic impact of national expert review and tested whether p53-IHC identifies subgroups in which review is high- or low-yield.
METHODS: The Dutch Oesophageal Pathology Panel reviewed consecutive BE cases submitted from 39 hospitals (2015-2024). Digitised haematoxylin and eosin-stained and p53-IHC slides were assessed by experienced gastrointestinal pathologists. Panel diagnoses required ≥ 75% agreement or consensus meeting review. Referring and panel diagnoses were compared at the patient level, with biopsy-level analyses assessing diagnostic shifts according to referring-centre p53-IHC status (wild-type, aberrant or equivocal).
RESULTS: The cohort included 1146 consecutive patients and 2187 biopsy levels, each assessed by a median of 12 panel pathologists. Expert review changed 46.9% of referring diagnoses (downgrading 24.7% and upgrading 22.2%). Indefinite for dysplasia (IND) was the most unstable diagnostic category, with 73.4% of cases reclassified. Among 1731 biopsy levels with reported p53-IHC at referral, p53-IHC strongly stratified review yield. Low-grade or high-grade dysplasia (LGD/HGD) with aberrant p53-IHC was confirmed in 91.7% of biopsy levels. In contrast, LGD/HGD with wild-type or equivocal p53-IHC showed substantially higher downgrade rates (53.6% and 32.8%), with odds ratios for diagnostic adjustment of 12.7 (95% CI: 8.2-19.7) and 5.4 (95% CI: 2.9-10.0) versus aberrant p53-IHC.
CONCLUSION: Expert review substantially altered BE dysplasia diagnoses, supporting current guideline recommendations. P53-IHC markedly stratified review yield: IND and dysplasia with wild-type or equivocal p53-IHC remain high-priority categories, whereas aberrant p53-IHC dysplasia was rarely reclassified. A p53-guided triage strategy could help optimise the use of expert pathology capacity, but prospective validation is needed before clinical implementation.
| Original language | English |
|---|---|
| Article number | e70309 |
| Journal | United European Gastroenterology Journal |
| Volume | 14 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Oct 2026 |
Keywords
- Humans
- Barrett Esophagus/pathology
- Tumor Suppressor Protein p53/analysis
- Triage/methods
- Referral and Consultation/standards
- Immunohistochemistry
- Female
- Male
- Biopsy
- Aged
- Middle Aged
- Netherlands
- Esophageal Neoplasms/pathology
- Esophagus/pathology
- Cohort Studies
Fingerprint
Dive into the research topics of 'Optimising Expert Pathology Referral in Barrett's Oesophagus Dysplasia Through p53-Guided Triage: A Nationwide Real-World Cohort Study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver